Cigna Stock Analysis: A Cannibal Machine Strategy

Cigna's Dual Business Model

• 💡 Cigna operates as a high-performance machine with two main engines: Cigna Healthcare (traditional insurance) and Evernorth, its "money printing machine" division.
• 🎯 Evernorth's crown jewel is the Pharmacy Benefit Manager (PBM), which manages prescription drug plans.

The Power of Pharmacy Benefit Managers (PBMs)

• 🔑 PBMs act as the ultimate middleman in the drug world, negotiating prices directly with pharmaceutical giants.
• 📈 By controlling access for millions of patients, PBMs wield unbelievable negotiating power, securing massive discounts and taking a small slice of each transaction.
• ✅ This business model is built on pure massive scale, ensuring profitability through high volume.

Strategic Moves and Shareholder Value

• 🚀 CEO David Cordani has made "strokes of genius" moves, including walking away from a Humana merger to protect shareholder value.
• 💰 Cigna sold its Medicare Advantage business for over $3 billion, sidestepping future government "squeezing Medicare reimbursement rates" that affect competitors.

Understanding the "Cannibal Stock" Approach

• 🧠 Cigna is identified as a "cannibal stock" because it systematically buys back its own shares.
• 📊 In the last 18 months, Cigna has bought back and erased a staggering 10% of its shares, significantly increasing the value of remaining shares for owners.
• 🔥 This strategy is considered one of the most shareholder-friendly actions a company can take, effectively giving existing owners a larger piece of the same "pizza."

Valuation and Market Perception

• 💸 Despite its strong business and strategy, Cigna is trading at a massive discount, with a 10% free cash flow yield.
• ⚠️ The market is "terrified" by scary headlines about government regulation of PBMs, causing the stock to be undervalued.
• ✅ Cigna's own executives, who know the business best, have been buying up stock with their personal money, suggesting market fears are "overblown."

Key Risks to Consider

• 🔍 The constant threat of FTC regulation against PBMs is largely considered "noise" due to the slow and complicated nature of meaningful change.
• 💊 The biggest "black swan event" risk is the explosion of new weight loss drugs like Ozempic (GLP-1 drugs), which are expensive and could seriously strain Cigna's costs if demand soars.